nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—PTGS2—skin cancer	0.301	1	CbGaD
Thalidomide—CYP1A2—Imiquimod—skin cancer	0.0661	0.175	CbGbCtD
Thalidomide—CYP1A1—Dacarbazine—skin cancer	0.0621	0.164	CbGbCtD
Thalidomide—CYP2C19—Vismodegib—skin cancer	0.0497	0.131	CbGbCtD
Thalidomide—CYP2E1—Dacarbazine—skin cancer	0.048	0.127	CbGbCtD
Thalidomide—CYP2C9—Vismodegib—skin cancer	0.0413	0.109	CbGbCtD
Thalidomide—CYP1A2—Vemurafenib—skin cancer	0.0362	0.0956	CbGbCtD
Thalidomide—CYP1A2—Dacarbazine—skin cancer	0.0278	0.0733	CbGbCtD
Thalidomide—CYP3A5—Docetaxel—skin cancer	0.0167	0.0441	CbGbCtD
Thalidomide—CYP1A2—Fluorouracil—skin cancer	0.0163	0.043	CbGbCtD
Thalidomide—CYP2C9—Fluorouracil—skin cancer	0.0147	0.0387	CbGbCtD
Thalidomide—FGFR2—skin epidermis—skin cancer	0.00404	0.0774	CbGeAlD
Thalidomide—NFKB1—nipple—skin cancer	0.0026	0.0499	CbGeAlD
Thalidomide—CRBN—nipple—skin cancer	0.00218	0.0418	CbGeAlD
Thalidomide—FGFR2—neck—skin cancer	0.00193	0.0371	CbGeAlD
Thalidomide—PTGS2—leg—skin cancer	0.00193	0.0369	CbGeAlD
Thalidomide—NFKB1—connective tissue—skin cancer	0.00184	0.0354	CbGeAlD
Thalidomide—PTGS2—hindlimb—skin cancer	0.00172	0.033	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—skin cancer	0.00157	0.518	CrCbGaD
Thalidomide—NFKB1—mammalian vulva—skin cancer	0.00152	0.0291	CbGeAlD
Thalidomide—PTGS2—appendage—skin cancer	0.00147	0.0283	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—skin cancer	0.00146	0.482	CrCbGaD
Thalidomide—CYP1A1—skin epidermis—skin cancer	0.00146	0.028	CbGeAlD
Thalidomide—FGFR2—connective tissue—skin cancer	0.00139	0.0266	CbGeAlD
Thalidomide—NFKB1—lymphoid tissue—skin cancer	0.00135	0.0259	CbGeAlD
Thalidomide—TNF—lymph node—skin cancer	0.00133	0.0256	CbGeAlD
Thalidomide—FGFR2—epithelium—skin cancer	0.00132	0.0252	CbGeAlD
Thalidomide—NFKB1—female reproductive system—skin cancer	0.0013	0.0249	CbGeAlD
Thalidomide—CRBN—mammalian vulva—skin cancer	0.00127	0.0244	CbGeAlD
Thalidomide—FGFR2—skin of body—skin cancer	0.00125	0.024	CbGeAlD
Thalidomide—PTGS2—skin epidermis—skin cancer	0.00123	0.0235	CbGeAlD
Thalidomide—CRBN—lymphoid tissue—skin cancer	0.00113	0.0217	CbGeAlD
Thalidomide—CRBN—female reproductive system—skin cancer	0.00109	0.0209	CbGeAlD
Thalidomide—NFKB1—head—skin cancer	0.00109	0.0208	CbGeAlD
Thalidomide—FGFR2—female reproductive system—skin cancer	0.000977	0.0187	CbGeAlD
Thalidomide—PTGS1—endothelium—skin cancer	0.000931	0.0179	CbGeAlD
Thalidomide—CRBN—head—skin cancer	0.000911	0.0175	CbGeAlD
Thalidomide—PTGS2—endothelium—skin cancer	0.00089	0.0171	CbGeAlD
Thalidomide—PTGS1—blood vessel—skin cancer	0.000859	0.0165	CbGeAlD
Thalidomide—PTGS2—blood vessel—skin cancer	0.000821	0.0157	CbGeAlD
Thalidomide—FGFR2—head—skin cancer	0.000816	0.0156	CbGeAlD
Thalidomide—NFKB1—lymph node—skin cancer	0.000761	0.0146	CbGeAlD
Thalidomide—CYP1A2—nipple—skin cancer	0.000717	0.0137	CbGeAlD
Thalidomide—CYP1A1—nipple—skin cancer	0.000707	0.0136	CbGeAlD
Thalidomide—CRBN—lymph node—skin cancer	0.000638	0.0122	CbGeAlD
Thalidomide—PTGS1—nipple—skin cancer	0.000621	0.0119	CbGeAlD
Thalidomide—CYP1A1—epithelium—skin cancer	0.000476	0.00913	CbGeAlD
Thalidomide—CYP1A1—skin of body—skin cancer	0.000453	0.00868	CbGeAlD
Thalidomide—PTGS1—connective tissue—skin cancer	0.00044	0.00844	CbGeAlD
Thalidomide—PTGS2—connective tissue—skin cancer	0.000421	0.00807	CbGeAlD
Thalidomide—PTGS1—epithelium—skin cancer	0.000418	0.00802	CbGeAlD
Thalidomide—CYP1A1—mammalian vulva—skin cancer	0.000413	0.00792	CbGeAlD
Thalidomide—PTGS2—epithelium—skin cancer	0.0004	0.00766	CbGeAlD
Thalidomide—PTGS1—skin of body—skin cancer	0.000398	0.00763	CbGeAlD
Thalidomide—PTGS2—skin of body—skin cancer	0.00038	0.00729	CbGeAlD
Thalidomide—PTGS1—mammalian vulva—skin cancer	0.000363	0.00695	CbGeAlD
Thalidomide—CYP1A1—female reproductive system—skin cancer	0.000354	0.00678	CbGeAlD
Thalidomide—CYP2C9—female reproductive system—skin cancer	0.00034	0.00652	CbGeAlD
Thalidomide—CYP2E1—lymphoid tissue—skin cancer	0.000334	0.00641	CbGeAlD
Thalidomide—CYP2E1—female reproductive system—skin cancer	0.000322	0.00618	CbGeAlD
Thalidomide—PTGS1—female reproductive system—skin cancer	0.000311	0.00596	CbGeAlD
Thalidomide—PTGS2—lymphoid tissue—skin cancer	0.000308	0.0059	CbGeAlD
Thalidomide—PTGS2—female reproductive system—skin cancer	0.000297	0.00569	CbGeAlD
Thalidomide—CYP1A1—head—skin cancer	0.000295	0.00566	CbGeAlD
Thalidomide—CYP2E1—head—skin cancer	0.000269	0.00516	CbGeAlD
Thalidomide—PTGS1—head—skin cancer	0.000259	0.00498	CbGeAlD
Thalidomide—PTGS2—head—skin cancer	0.000248	0.00476	CbGeAlD
Thalidomide—CYP1A1—lymph node—skin cancer	0.000207	0.00397	CbGeAlD
Thalidomide—PTGS1—lymph node—skin cancer	0.000182	0.00348	CbGeAlD
Thalidomide—PTGS2—lymph node—skin cancer	0.000174	0.00333	CbGeAlD
Thalidomide—Chest pain—Bleomycin—skin cancer	0.000141	0.00071	CcSEcCtD
Thalidomide—Myalgia—Bleomycin—skin cancer	0.000141	0.00071	CcSEcCtD
Thalidomide—Orthostatic hypotension—Docetaxel—skin cancer	0.000141	0.00071	CcSEcCtD
Thalidomide—Rash—Vemurafenib—skin cancer	0.000141	0.000708	CcSEcCtD
Thalidomide—Mental disorder—Temozolomide—skin cancer	0.00014	0.000708	CcSEcCtD
Thalidomide—Dermatitis—Vemurafenib—skin cancer	0.00014	0.000708	CcSEcCtD
Thalidomide—Hypersensitivity—Imiquimod—skin cancer	0.00014	0.000706	CcSEcCtD
Thalidomide—Headache—Vemurafenib—skin cancer	0.00014	0.000704	CcSEcCtD
Thalidomide—Malnutrition—Temozolomide—skin cancer	0.00014	0.000703	CcSEcCtD
Thalidomide—Breast disorder—Docetaxel—skin cancer	0.000139	0.000702	CcSEcCtD
Thalidomide—Discomfort—Bleomycin—skin cancer	0.000139	0.000701	CcSEcCtD
Thalidomide—Malaise—Dactinomycin—skin cancer	0.000139	0.000701	CcSEcCtD
Thalidomide—Cramp muscle—Docetaxel—skin cancer	0.000139	0.0007	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000139	0.0007	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000139	0.0007	CcSEcCtD
Thalidomide—Leukopenia—Dactinomycin—skin cancer	0.000138	0.000696	CcSEcCtD
Thalidomide—Dysgeusia—Temozolomide—skin cancer	0.000137	0.000689	CcSEcCtD
Thalidomide—Asthenia—Imiquimod—skin cancer	0.000136	0.000687	CcSEcCtD
Thalidomide—Confusional state—Bleomycin—skin cancer	0.000136	0.000686	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000136	0.000685	CcSEcCtD
Thalidomide—Oedema—Bleomycin—skin cancer	0.000135	0.000681	CcSEcCtD
Thalidomide—Back pain—Temozolomide—skin cancer	0.000135	0.00068	CcSEcCtD
Thalidomide—Pruritus—Imiquimod—skin cancer	0.000135	0.000678	CcSEcCtD
Thalidomide—Infection—Bleomycin—skin cancer	0.000134	0.000676	CcSEcCtD
Thalidomide—Dysphagia—Docetaxel—skin cancer	0.000133	0.000671	CcSEcCtD
Thalidomide—Nausea—Vemurafenib—skin cancer	0.000132	0.000667	CcSEcCtD
Thalidomide—Thrombocytopenia—Bleomycin—skin cancer	0.000132	0.000666	CcSEcCtD
Thalidomide—Arrhythmia—Fluorouracil—skin cancer	0.000132	0.000665	CcSEcCtD
Thalidomide—Vision blurred—Temozolomide—skin cancer	0.000132	0.000663	CcSEcCtD
Thalidomide—Myalgia—Dactinomycin—skin cancer	0.000131	0.000662	CcSEcCtD
Thalidomide—Bronchospasm—Docetaxel—skin cancer	0.000131	0.00066	CcSEcCtD
Thalidomide—Tremor—Temozolomide—skin cancer	0.000131	0.000659	CcSEcCtD
Thalidomide—Alopecia—Fluorouracil—skin cancer	0.000131	0.000658	CcSEcCtD
Thalidomide—Diarrhoea—Imiquimod—skin cancer	0.00013	0.000656	CcSEcCtD
Thalidomide—Discomfort—Dactinomycin—skin cancer	0.00013	0.000654	CcSEcCtD
Thalidomide—Angina pectoris—Docetaxel—skin cancer	0.00013	0.000654	CcSEcCtD
Thalidomide—Ill-defined disorder—Temozolomide—skin cancer	0.00013	0.000653	CcSEcCtD
Thalidomide—Anaemia—Temozolomide—skin cancer	0.000129	0.00065	CcSEcCtD
Thalidomide—Anorexia—Bleomycin—skin cancer	0.000129	0.000649	CcSEcCtD
Thalidomide—Agitation—Temozolomide—skin cancer	0.000128	0.000646	CcSEcCtD
Thalidomide—Angioedema—Temozolomide—skin cancer	0.000128	0.000643	CcSEcCtD
Thalidomide—Pancytopenia—Docetaxel—skin cancer	0.000127	0.000638	CcSEcCtD
Thalidomide—Hypotension—Bleomycin—skin cancer	0.000126	0.000636	CcSEcCtD
Thalidomide—Oedema—Dactinomycin—skin cancer	0.000126	0.000635	CcSEcCtD
Thalidomide—Malaise—Temozolomide—skin cancer	0.000126	0.000634	CcSEcCtD
Thalidomide—Dizziness—Imiquimod—skin cancer	0.000126	0.000634	CcSEcCtD
Thalidomide—Vertigo—Temozolomide—skin cancer	0.000125	0.000632	CcSEcCtD
Thalidomide—Infection—Dactinomycin—skin cancer	0.000125	0.000631	CcSEcCtD
Thalidomide—Leukopenia—Temozolomide—skin cancer	0.000125	0.00063	CcSEcCtD
Thalidomide—Neutropenia—Docetaxel—skin cancer	0.000125	0.000628	CcSEcCtD
Thalidomide—Palpitations—Temozolomide—skin cancer	0.000123	0.000622	CcSEcCtD
Thalidomide—Thrombocytopenia—Dactinomycin—skin cancer	0.000123	0.000622	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000123	0.00062	CcSEcCtD
Thalidomide—Cough—Temozolomide—skin cancer	0.000122	0.000614	CcSEcCtD
Thalidomide—Paraesthesia—Bleomycin—skin cancer	0.000121	0.000611	CcSEcCtD
Thalidomide—Weight increased—Docetaxel—skin cancer	0.000121	0.000611	CcSEcCtD
Thalidomide—Vision blurred—Fluorouracil—skin cancer	0.000121	0.000611	CcSEcCtD
Thalidomide—Convulsion—Temozolomide—skin cancer	0.000121	0.00061	CcSEcCtD
Thalidomide—Vomiting—Imiquimod—skin cancer	0.000121	0.000609	CcSEcCtD
Thalidomide—Weight decreased—Docetaxel—skin cancer	0.000121	0.000607	CcSEcCtD
Thalidomide—Hypertension—Temozolomide—skin cancer	0.000121	0.000607	CcSEcCtD
Thalidomide—Dyspnoea—Bleomycin—skin cancer	0.00012	0.000607	CcSEcCtD
Thalidomide—Anorexia—Dactinomycin—skin cancer	0.00012	0.000605	CcSEcCtD
Thalidomide—Rash—Imiquimod—skin cancer	0.00012	0.000604	CcSEcCtD
Thalidomide—Dermatitis—Imiquimod—skin cancer	0.00012	0.000604	CcSEcCtD
Thalidomide—Pneumonia—Docetaxel—skin cancer	0.000119	0.000602	CcSEcCtD
Thalidomide—Headache—Imiquimod—skin cancer	0.000119	0.0006	CcSEcCtD
Thalidomide—Anaemia—Fluorouracil—skin cancer	0.000119	0.000599	CcSEcCtD
Thalidomide—Myalgia—Temozolomide—skin cancer	0.000119	0.000599	CcSEcCtD
Thalidomide—Arthralgia—Temozolomide—skin cancer	0.000119	0.000599	CcSEcCtD
Thalidomide—Infestation NOS—Docetaxel—skin cancer	0.000119	0.000599	CcSEcCtD
Thalidomide—Infestation—Docetaxel—skin cancer	0.000119	0.000599	CcSEcCtD
Thalidomide—Anxiety—Temozolomide—skin cancer	0.000118	0.000597	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000118	0.000595	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000118	0.000594	CcSEcCtD
Thalidomide—Discomfort—Temozolomide—skin cancer	0.000117	0.000592	CcSEcCtD
Thalidomide—Decreased appetite—Bleomycin—skin cancer	0.000117	0.000592	CcSEcCtD
Thalidomide—Acute coronary syndrome—Docetaxel—skin cancer	0.000117	0.00059	CcSEcCtD
Thalidomide—Renal failure—Docetaxel—skin cancer	0.000117	0.000588	CcSEcCtD
Thalidomide—Myocardial infarction—Docetaxel—skin cancer	0.000116	0.000587	CcSEcCtD
Thalidomide—Neuropathy peripheral—Docetaxel—skin cancer	0.000116	0.000587	CcSEcCtD
Thalidomide—Dry mouth—Temozolomide—skin cancer	0.000116	0.000586	CcSEcCtD
Thalidomide—Stomatitis—Docetaxel—skin cancer	0.000116	0.000584	CcSEcCtD
Thalidomide—Pain—Bleomycin—skin cancer	0.000116	0.000582	CcSEcCtD
Thalidomide—Conjunctivitis—Docetaxel—skin cancer	0.000115	0.000582	CcSEcCtD
Thalidomide—Leukopenia—Fluorouracil—skin cancer	0.000115	0.00058	CcSEcCtD
Thalidomide—Confusional state—Temozolomide—skin cancer	0.000115	0.000579	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000115	0.000578	CcSEcCtD
Thalidomide—Oedema—Temozolomide—skin cancer	0.000114	0.000574	CcSEcCtD
Thalidomide—Infection—Temozolomide—skin cancer	0.000113	0.00057	CcSEcCtD
Thalidomide—Nausea—Imiquimod—skin cancer	0.000113	0.000569	CcSEcCtD
Thalidomide—Epistaxis—Docetaxel—skin cancer	0.000112	0.000565	CcSEcCtD
Thalidomide—Nervous system disorder—Temozolomide—skin cancer	0.000112	0.000563	CcSEcCtD
Thalidomide—Thrombocytopenia—Temozolomide—skin cancer	0.000112	0.000562	CcSEcCtD
Thalidomide—Convulsion—Fluorouracil—skin cancer	0.000111	0.000562	CcSEcCtD
Thalidomide—Feeling abnormal—Bleomycin—skin cancer	0.000111	0.000561	CcSEcCtD
Thalidomide—Agranulocytosis—Docetaxel—skin cancer	0.000111	0.000559	CcSEcCtD
Thalidomide—Skin disorder—Temozolomide—skin cancer	0.000111	0.000558	CcSEcCtD
Thalidomide—Hyperhidrosis—Temozolomide—skin cancer	0.00011	0.000555	CcSEcCtD
Thalidomide—Chest pain—Fluorouracil—skin cancer	0.00011	0.000552	CcSEcCtD
Thalidomide—Myalgia—Fluorouracil—skin cancer	0.00011	0.000552	CcSEcCtD
Thalidomide—Decreased appetite—Dactinomycin—skin cancer	0.00011	0.000552	CcSEcCtD
Thalidomide—Fatigue—Dactinomycin—skin cancer	0.000109	0.000547	CcSEcCtD
Thalidomide—Anorexia—Temozolomide—skin cancer	0.000109	0.000547	CcSEcCtD
Thalidomide—Discomfort—Fluorouracil—skin cancer	0.000108	0.000545	CcSEcCtD
Thalidomide—Pain—Dactinomycin—skin cancer	0.000108	0.000543	CcSEcCtD
Thalidomide—Urticaria—Bleomycin—skin cancer	0.000107	0.000541	CcSEcCtD
Thalidomide—Rhinitis—Docetaxel—skin cancer	0.000107	0.000539	CcSEcCtD
Thalidomide—Body temperature increased—Bleomycin—skin cancer	0.000107	0.000538	CcSEcCtD
Thalidomide—Hepatitis—Docetaxel—skin cancer	0.000107	0.000537	CcSEcCtD
Thalidomide—Hypoaesthesia—Docetaxel—skin cancer	0.000106	0.000535	CcSEcCtD
Thalidomide—Confusional state—Fluorouracil—skin cancer	0.000106	0.000533	CcSEcCtD
Thalidomide—Pharyngitis—Docetaxel—skin cancer	0.000106	0.000533	CcSEcCtD
Thalidomide—Urinary tract disorder—Docetaxel—skin cancer	0.000105	0.000531	CcSEcCtD
Thalidomide—Oedema peripheral—Docetaxel—skin cancer	0.000105	0.000529	CcSEcCtD
Thalidomide—Oedema—Fluorouracil—skin cancer	0.000105	0.000529	CcSEcCtD
Thalidomide—Urethral disorder—Docetaxel—skin cancer	0.000105	0.000527	CcSEcCtD
Thalidomide—Infection—Fluorouracil—skin cancer	0.000104	0.000526	CcSEcCtD
Thalidomide—Feeling abnormal—Dactinomycin—skin cancer	0.000104	0.000523	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000104	0.000523	CcSEcCtD
Thalidomide—Insomnia—Temozolomide—skin cancer	0.000103	0.000519	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dactinomycin—skin cancer	0.000103	0.000519	CcSEcCtD
Thalidomide—Nervous system disorder—Fluorouracil—skin cancer	0.000103	0.000519	CcSEcCtD
Thalidomide—Thrombocytopenia—Fluorouracil—skin cancer	0.000103	0.000518	CcSEcCtD
Thalidomide—Visual impairment—Docetaxel—skin cancer	0.000103	0.000518	CcSEcCtD
Thalidomide—Tachycardia—Fluorouracil—skin cancer	0.000102	0.000516	CcSEcCtD
Thalidomide—Paraesthesia—Temozolomide—skin cancer	0.000102	0.000516	CcSEcCtD
Thalidomide—Dyspnoea—Temozolomide—skin cancer	0.000102	0.000512	CcSEcCtD
Thalidomide—Somnolence—Temozolomide—skin cancer	0.000101	0.00051	CcSEcCtD
Thalidomide—Erythema multiforme—Docetaxel—skin cancer	0.000101	0.000508	CcSEcCtD
Thalidomide—Dyspepsia—Temozolomide—skin cancer	0.0001	0.000505	CcSEcCtD
Thalidomide—Anorexia—Fluorouracil—skin cancer	0.0001	0.000504	CcSEcCtD
Thalidomide—Eye disorder—Docetaxel—skin cancer	9.97e-05	0.000502	CcSEcCtD
Thalidomide—Abdominal pain—Dactinomycin—skin cancer	9.96e-05	0.000502	CcSEcCtD
Thalidomide—Body temperature increased—Dactinomycin—skin cancer	9.96e-05	0.000502	CcSEcCtD
Thalidomide—Hypersensitivity—Bleomycin—skin cancer	9.95e-05	0.000501	CcSEcCtD
Thalidomide—Decreased appetite—Temozolomide—skin cancer	9.9e-05	0.000499	CcSEcCtD
Thalidomide—Cardiac disorder—Docetaxel—skin cancer	9.9e-05	0.000499	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Temozolomide—skin cancer	9.84e-05	0.000496	CcSEcCtD
Thalidomide—Fatigue—Temozolomide—skin cancer	9.82e-05	0.000495	CcSEcCtD
Thalidomide—Hypotension—Fluorouracil—skin cancer	9.81e-05	0.000494	CcSEcCtD
Thalidomide—Constipation—Temozolomide—skin cancer	9.74e-05	0.000491	CcSEcCtD
Thalidomide—Pain—Temozolomide—skin cancer	9.74e-05	0.000491	CcSEcCtD
Thalidomide—Asthenia—Bleomycin—skin cancer	9.69e-05	0.000488	CcSEcCtD
Thalidomide—Angiopathy—Docetaxel—skin cancer	9.68e-05	0.000488	CcSEcCtD
Thalidomide—Immune system disorder—Docetaxel—skin cancer	9.63e-05	0.000485	CcSEcCtD
Thalidomide—Mediastinal disorder—Docetaxel—skin cancer	9.61e-05	0.000484	CcSEcCtD
Thalidomide—Chills—Docetaxel—skin cancer	9.57e-05	0.000482	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Fluorouracil—skin cancer	9.56e-05	0.000482	CcSEcCtD
Thalidomide—Pruritus—Bleomycin—skin cancer	9.56e-05	0.000482	CcSEcCtD
Thalidomide—Arrhythmia—Docetaxel—skin cancer	9.53e-05	0.00048	CcSEcCtD
Thalidomide—Insomnia—Fluorouracil—skin cancer	9.49e-05	0.000478	CcSEcCtD
Thalidomide—Paraesthesia—Fluorouracil—skin cancer	9.43e-05	0.000475	CcSEcCtD
Thalidomide—Alopecia—Docetaxel—skin cancer	9.42e-05	0.000475	CcSEcCtD
Thalidomide—Feeling abnormal—Temozolomide—skin cancer	9.39e-05	0.000473	CcSEcCtD
Thalidomide—Dyspnoea—Fluorouracil—skin cancer	9.36e-05	0.000472	CcSEcCtD
Thalidomide—Mental disorder—Docetaxel—skin cancer	9.34e-05	0.000471	CcSEcCtD
Thalidomide—Somnolence—Fluorouracil—skin cancer	9.33e-05	0.00047	CcSEcCtD
Thalidomide—Gastrointestinal pain—Temozolomide—skin cancer	9.32e-05	0.000469	CcSEcCtD
Thalidomide—Malnutrition—Docetaxel—skin cancer	9.28e-05	0.000468	CcSEcCtD
Thalidomide—Hypersensitivity—Dactinomycin—skin cancer	9.28e-05	0.000468	CcSEcCtD
Thalidomide—Dyspepsia—Fluorouracil—skin cancer	9.24e-05	0.000466	CcSEcCtD
Thalidomide—Decreased appetite—Fluorouracil—skin cancer	9.13e-05	0.00046	CcSEcCtD
Thalidomide—Dysgeusia—Docetaxel—skin cancer	9.09e-05	0.000458	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Fluorouracil—skin cancer	9.06e-05	0.000457	CcSEcCtD
Thalidomide—Urticaria—Temozolomide—skin cancer	9.05e-05	0.000456	CcSEcCtD
Thalidomide—Asthenia—Dactinomycin—skin cancer	9.04e-05	0.000455	CcSEcCtD
Thalidomide—Abdominal pain—Temozolomide—skin cancer	9.01e-05	0.000454	CcSEcCtD
Thalidomide—Body temperature increased—Temozolomide—skin cancer	9.01e-05	0.000454	CcSEcCtD
Thalidomide—Back pain—Docetaxel—skin cancer	8.98e-05	0.000453	CcSEcCtD
Thalidomide—Pain—Fluorouracil—skin cancer	8.98e-05	0.000452	CcSEcCtD
Thalidomide—Muscle spasms—Docetaxel—skin cancer	8.93e-05	0.00045	CcSEcCtD
Thalidomide—Feeling abnormal—Fluorouracil—skin cancer	8.65e-05	0.000436	CcSEcCtD
Thalidomide—Diarrhoea—Dactinomycin—skin cancer	8.62e-05	0.000434	CcSEcCtD
Thalidomide—Vomiting—Bleomycin—skin cancer	8.59e-05	0.000433	CcSEcCtD
Thalidomide—Anaemia—Docetaxel—skin cancer	8.58e-05	0.000432	CcSEcCtD
Thalidomide—Rash—Bleomycin—skin cancer	8.52e-05	0.000429	CcSEcCtD
Thalidomide—Dermatitis—Bleomycin—skin cancer	8.51e-05	0.000429	CcSEcCtD
Thalidomide—Hypersensitivity—Temozolomide—skin cancer	8.39e-05	0.000423	CcSEcCtD
Thalidomide—Urticaria—Fluorouracil—skin cancer	8.34e-05	0.00042	CcSEcCtD
Thalidomide—Syncope—Docetaxel—skin cancer	8.33e-05	0.00042	CcSEcCtD
Thalidomide—Leukopenia—Docetaxel—skin cancer	8.31e-05	0.000419	CcSEcCtD
Thalidomide—Body temperature increased—Fluorouracil—skin cancer	8.3e-05	0.000418	CcSEcCtD
Thalidomide—Palpitations—Docetaxel—skin cancer	8.2e-05	0.000413	CcSEcCtD
Thalidomide—Asthenia—Temozolomide—skin cancer	8.17e-05	0.000412	CcSEcCtD
Thalidomide—Loss of consciousness—Docetaxel—skin cancer	8.16e-05	0.000411	CcSEcCtD
Thalidomide—Cough—Docetaxel—skin cancer	8.1e-05	0.000408	CcSEcCtD
Thalidomide—Pruritus—Temozolomide—skin cancer	8.06e-05	0.000406	CcSEcCtD
Thalidomide—Convulsion—Docetaxel—skin cancer	8.04e-05	0.000405	CcSEcCtD
Thalidomide—Nausea—Bleomycin—skin cancer	8.02e-05	0.000404	CcSEcCtD
Thalidomide—Hypertension—Docetaxel—skin cancer	8.02e-05	0.000404	CcSEcCtD
Thalidomide—Vomiting—Dactinomycin—skin cancer	8.01e-05	0.000404	CcSEcCtD
Thalidomide—Rash—Dactinomycin—skin cancer	7.94e-05	0.0004	CcSEcCtD
Thalidomide—Chest pain—Docetaxel—skin cancer	7.9e-05	0.000398	CcSEcCtD
Thalidomide—Arthralgia—Docetaxel—skin cancer	7.9e-05	0.000398	CcSEcCtD
Thalidomide—Myalgia—Docetaxel—skin cancer	7.9e-05	0.000398	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	7.85e-05	0.000396	CcSEcCtD
Thalidomide—Diarrhoea—Temozolomide—skin cancer	7.8e-05	0.000393	CcSEcCtD
Thalidomide—Hypersensitivity—Fluorouracil—skin cancer	7.73e-05	0.00039	CcSEcCtD
Thalidomide—Dry mouth—Docetaxel—skin cancer	7.73e-05	0.00039	CcSEcCtD
Thalidomide—Confusional state—Docetaxel—skin cancer	7.64e-05	0.000385	CcSEcCtD
Thalidomide—Oedema—Docetaxel—skin cancer	7.58e-05	0.000382	CcSEcCtD
Thalidomide—Dizziness—Temozolomide—skin cancer	7.53e-05	0.00038	CcSEcCtD
Thalidomide—Infection—Docetaxel—skin cancer	7.53e-05	0.000379	CcSEcCtD
Thalidomide—Nausea—Dactinomycin—skin cancer	7.48e-05	0.000377	CcSEcCtD
Thalidomide—Shock—Docetaxel—skin cancer	7.45e-05	0.000376	CcSEcCtD
Thalidomide—Nervous system disorder—Docetaxel—skin cancer	7.43e-05	0.000374	CcSEcCtD
Thalidomide—Pruritus—Fluorouracil—skin cancer	7.43e-05	0.000374	CcSEcCtD
Thalidomide—Thrombocytopenia—Docetaxel—skin cancer	7.42e-05	0.000374	CcSEcCtD
Thalidomide—Tachycardia—Docetaxel—skin cancer	7.39e-05	0.000373	CcSEcCtD
Thalidomide—Skin disorder—Docetaxel—skin cancer	7.36e-05	0.000371	CcSEcCtD
Thalidomide—Vomiting—Temozolomide—skin cancer	7.24e-05	0.000365	CcSEcCtD
Thalidomide—Anorexia—Docetaxel—skin cancer	7.22e-05	0.000364	CcSEcCtD
Thalidomide—Rash—Temozolomide—skin cancer	7.18e-05	0.000362	CcSEcCtD
Thalidomide—Diarrhoea—Fluorouracil—skin cancer	7.18e-05	0.000362	CcSEcCtD
Thalidomide—Dermatitis—Temozolomide—skin cancer	7.18e-05	0.000362	CcSEcCtD
Thalidomide—Headache—Temozolomide—skin cancer	7.14e-05	0.00036	CcSEcCtD
Thalidomide—Hypotension—Docetaxel—skin cancer	7.08e-05	0.000357	CcSEcCtD
Thalidomide—Dizziness—Fluorouracil—skin cancer	6.94e-05	0.00035	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Docetaxel—skin cancer	6.9e-05	0.000348	CcSEcCtD
Thalidomide—Insomnia—Docetaxel—skin cancer	6.85e-05	0.000345	CcSEcCtD
Thalidomide—Paraesthesia—Docetaxel—skin cancer	6.8e-05	0.000343	CcSEcCtD
Thalidomide—Nausea—Temozolomide—skin cancer	6.77e-05	0.000341	CcSEcCtD
Thalidomide—Dyspnoea—Docetaxel—skin cancer	6.75e-05	0.00034	CcSEcCtD
Thalidomide—Somnolence—Docetaxel—skin cancer	6.74e-05	0.000339	CcSEcCtD
Thalidomide—Vomiting—Fluorouracil—skin cancer	6.67e-05	0.000336	CcSEcCtD
Thalidomide—Dyspepsia—Docetaxel—skin cancer	6.67e-05	0.000336	CcSEcCtD
Thalidomide—Rash—Fluorouracil—skin cancer	6.62e-05	0.000334	CcSEcCtD
Thalidomide—Dermatitis—Fluorouracil—skin cancer	6.61e-05	0.000333	CcSEcCtD
Thalidomide—Decreased appetite—Docetaxel—skin cancer	6.59e-05	0.000332	CcSEcCtD
Thalidomide—Headache—Fluorouracil—skin cancer	6.58e-05	0.000331	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Docetaxel—skin cancer	6.54e-05	0.00033	CcSEcCtD
Thalidomide—Fatigue—Docetaxel—skin cancer	6.53e-05	0.000329	CcSEcCtD
Thalidomide—Constipation—Docetaxel—skin cancer	6.48e-05	0.000327	CcSEcCtD
Thalidomide—Pain—Docetaxel—skin cancer	6.48e-05	0.000327	CcSEcCtD
Thalidomide—Feeling abnormal—Docetaxel—skin cancer	6.24e-05	0.000315	CcSEcCtD
Thalidomide—Nausea—Fluorouracil—skin cancer	6.24e-05	0.000314	CcSEcCtD
Thalidomide—Gastrointestinal pain—Docetaxel—skin cancer	6.2e-05	0.000312	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—KRAS—skin cancer	6.12e-05	0.000922	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—IL6—skin cancer	6.09e-05	0.000918	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—NRAS—skin cancer	6.08e-05	0.000917	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by Insulin receptor—IL6—skin cancer	6.08e-05	0.000916	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—NRAS—skin cancer	6.06e-05	0.000913	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—NRAS—skin cancer	6.04e-05	0.00091	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—KRAS—skin cancer	6.02e-05	0.000907	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	6.01e-05	0.000906	CbGpPWpGaD
Thalidomide—Body temperature increased—Docetaxel—skin cancer	5.99e-05	0.000302	CcSEcCtD
Thalidomide—Abdominal pain—Docetaxel—skin cancer	5.99e-05	0.000302	CcSEcCtD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.91e-05	0.000891	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	5.88e-05	0.000887	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—IL6—skin cancer	5.88e-05	0.000886	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	5.87e-05	0.000884	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—KRAS—skin cancer	5.86e-05	0.000883	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—KRAS—skin cancer	5.75e-05	0.000866	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—NRAS—skin cancer	5.73e-05	0.000864	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—KRAS—skin cancer	5.72e-05	0.000862	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—KRAS—skin cancer	5.69e-05	0.000858	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—skin cancer	5.67e-05	0.000854	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—KRAS—skin cancer	5.66e-05	0.000854	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—HRAS—skin cancer	5.63e-05	0.000849	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	5.62e-05	0.000846	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	5.58e-05	0.000841	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	5.58e-05	0.000841	CbGpPWpGaD
Thalidomide—Hypersensitivity—Docetaxel—skin cancer	5.58e-05	0.000281	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	5.54e-05	0.000835	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	5.48e-05	0.000826	CbGpPWpGaD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—IL6—skin cancer	5.48e-05	0.000826	CbGpPWpGaD
Thalidomide—Asthenia—Docetaxel—skin cancer	5.44e-05	0.000274	CcSEcCtD
Thalidomide—FGFR2—Signaling by SCF-KIT—HRAS—skin cancer	5.43e-05	0.000819	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—skin cancer	5.41e-05	0.000815	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.39e-05	0.000812	CbGpPWpGaD
Thalidomide—Pruritus—Docetaxel—skin cancer	5.36e-05	0.00027	CcSEcCtD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	5.33e-05	0.000803	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—KRAS—skin cancer	5.33e-05	0.000803	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—KRAS—skin cancer	5.33e-05	0.000803	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.29e-05	0.000796	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—KRAS—skin cancer	5.28e-05	0.000796	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TP53—skin cancer	5.26e-05	0.000793	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—KRAS—skin cancer	5.24e-05	0.000789	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—KRAS—skin cancer	5.21e-05	0.000785	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—skin cancer	5.21e-05	0.000784	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	5.2e-05	0.000784	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—IL6—skin cancer	5.2e-05	0.000784	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—HRAS—skin cancer	5.2e-05	0.000783	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—KRAS—skin cancer	5.2e-05	0.000783	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—NRAS—skin cancer	5.18e-05	0.000781	CbGpPWpGaD
Thalidomide—Diarrhoea—Docetaxel—skin cancer	5.18e-05	0.000261	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—GLI2—skin cancer	5.18e-05	0.000781	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CDK4—skin cancer	5.16e-05	0.000778	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—HRAS—skin cancer	5.12e-05	0.000771	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	5.11e-05	0.000771	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	5.08e-05	0.000766	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL6—skin cancer	5.06e-05	0.000762	CbGpPWpGaD
Thalidomide—Dizziness—Docetaxel—skin cancer	5.01e-05	0.000252	CcSEcCtD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	5e-05	0.000754	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—IL6—skin cancer	4.98e-05	0.00075	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MC1R—skin cancer	4.95e-05	0.000745	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—KRAS—skin cancer	4.93e-05	0.000743	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GLI2—skin cancer	4.92e-05	0.000741	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—IL6—skin cancer	4.9e-05	0.000738	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—HRAS—skin cancer	4.89e-05	0.000736	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GLI1—skin cancer	4.87e-05	0.000734	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—HRAS—skin cancer	4.86e-05	0.000733	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—HRAS—skin cancer	4.84e-05	0.000729	CbGpPWpGaD
Thalidomide—Vomiting—Docetaxel—skin cancer	4.82e-05	0.000243	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—IL6—skin cancer	4.82e-05	0.000726	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—HRAS—skin cancer	4.82e-05	0.000726	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	4.8e-05	0.000724	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—skin cancer	4.8e-05	0.000723	CbGpPWpGaD
Thalidomide—Rash—Docetaxel—skin cancer	4.78e-05	0.000241	CcSEcCtD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	4.77e-05	0.000719	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SHH—skin cancer	4.77e-05	0.000719	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ENO2—skin cancer	4.77e-05	0.000719	CbGpPWpGaD
Thalidomide—Dermatitis—Docetaxel—skin cancer	4.77e-05	0.000241	CcSEcCtD
Thalidomide—Headache—Docetaxel—skin cancer	4.75e-05	0.000239	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	4.75e-05	0.000715	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL6—skin cancer	4.74e-05	0.000715	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	4.72e-05	0.000711	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.7e-05	0.000708	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MC1R—skin cancer	4.69e-05	0.000707	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—IL6—skin cancer	4.68e-05	0.000705	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—IL6—skin cancer	4.65e-05	0.000701	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—IL6—skin cancer	4.63e-05	0.000698	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GLI1—skin cancer	4.62e-05	0.000697	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SUFU—skin cancer	4.62e-05	0.000696	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—IL6—skin cancer	4.61e-05	0.000694	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.6e-05	0.000694	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	4.57e-05	0.000689	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLIN2—skin cancer	4.57e-05	0.000688	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	4.53e-05	0.000683	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HRAS—skin cancer	4.53e-05	0.000683	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—HRAS—skin cancer	4.53e-05	0.000683	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—NRAS—skin cancer	4.52e-05	0.000681	CbGpPWpGaD
Thalidomide—Nausea—Docetaxel—skin cancer	4.5e-05	0.000227	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR—HRAS—skin cancer	4.49e-05	0.000677	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—KRAS—skin cancer	4.46e-05	0.000672	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—IL6—skin cancer	4.46e-05	0.000672	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—HRAS—skin cancer	4.45e-05	0.000671	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—NRAS—skin cancer	4.45e-05	0.00067	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FOXO4—skin cancer	4.44e-05	0.000669	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—HRAS—skin cancer	4.43e-05	0.000668	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—HRAS—skin cancer	4.42e-05	0.000666	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	4.4e-05	0.000663	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—IL6—skin cancer	4.39e-05	0.000662	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SUFU—skin cancer	4.38e-05	0.000661	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—IL6—skin cancer	4.34e-05	0.000653	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	4.34e-05	0.000653	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—IL6—skin cancer	4.34e-05	0.000653	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—IL6—skin cancer	4.3e-05	0.000648	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—IL6—skin cancer	4.26e-05	0.000642	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—IL6—skin cancer	4.24e-05	0.000639	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—skin cancer	4.23e-05	0.000637	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—skin cancer	4.22e-05	0.000637	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NRAS—skin cancer	4.22e-05	0.000636	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FOXO4—skin cancer	4.22e-05	0.000635	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—HRAS—skin cancer	4.19e-05	0.000632	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	4.08e-05	0.000615	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	4.03e-05	0.000607	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	4.01e-05	0.000605	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—skin cancer	3.97e-05	0.000598	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CDK4—skin cancer	3.93e-05	0.000593	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FOXO4—skin cancer	3.89e-05	0.000586	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—KRAS—skin cancer	3.89e-05	0.000586	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL6—skin cancer	3.85e-05	0.00058	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	3.84e-05	0.000579	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—KRAS—skin cancer	3.83e-05	0.000577	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	3.77e-05	0.000567	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	3.74e-05	0.000564	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CSPG4—skin cancer	3.68e-05	0.000554	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—KRAS—skin cancer	3.63e-05	0.000547	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—skin cancer	3.63e-05	0.000546	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLIN2—skin cancer	3.62e-05	0.000546	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.58e-05	0.000539	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SHH—skin cancer	3.52e-05	0.000531	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RASA1—skin cancer	3.5e-05	0.000528	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CSPG4—skin cancer	3.49e-05	0.000526	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLIN2—skin cancer	3.41e-05	0.000514	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLIN2—skin cancer	3.4e-05	0.000513	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SHH—skin cancer	3.34e-05	0.000504	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SMO—skin cancer	3.34e-05	0.000503	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTCH1—skin cancer	3.34e-05	0.000503	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RASA1—skin cancer	3.32e-05	0.000501	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—skin cancer	3.32e-05	0.0005	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—skin cancer	3.31e-05	0.000498	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—skin cancer	3.25e-05	0.00049	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—skin cancer	3.25e-05	0.00049	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTGER4—skin cancer	3.25e-05	0.00049	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLIN2—skin cancer	3.22e-05	0.000485	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTCH1—skin cancer	3.17e-05	0.000478	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SMO—skin cancer	3.17e-05	0.000478	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—skin cancer	3.17e-05	0.000477	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—skin cancer	3.11e-05	0.000469	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—skin cancer	3.09e-05	0.000465	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTGER4—skin cancer	3.09e-05	0.000465	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—skin cancer	2.98e-05	0.000449	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—skin cancer	2.95e-05	0.000445	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CSPG4—skin cancer	2.92e-05	0.00044	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FOXO4—skin cancer	2.87e-05	0.000433	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—NRAS—skin cancer	2.87e-05	0.000433	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERCC2—skin cancer	2.77e-05	0.000418	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CSPG4—skin cancer	2.75e-05	0.000414	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CSPG4—skin cancer	2.74e-05	0.000414	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FOXO4—skin cancer	2.73e-05	0.000411	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLIN2—skin cancer	2.63e-05	0.000397	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TERT—skin cancer	2.6e-05	0.000392	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CSPG4—skin cancer	2.59e-05	0.000391	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—NRAS—skin cancer	2.54e-05	0.000382	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ENO2—skin cancer	2.5e-05	0.000377	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.49e-05	0.000375	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KRAS—skin cancer	2.47e-05	0.000372	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—skin cancer	2.43e-05	0.000367	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—skin cancer	2.41e-05	0.000363	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLIN2—skin cancer	2.4e-05	0.000362	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ENO2—skin cancer	2.37e-05	0.000357	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SHH—skin cancer	2.37e-05	0.000357	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—skin cancer	2.31e-05	0.000348	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.21e-05	0.000334	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NRAS—skin cancer	2.19e-05	0.00033	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KRAS—skin cancer	2.18e-05	0.000329	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CSPG4—skin cancer	2.12e-05	0.00032	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—skin cancer	2.1e-05	0.000317	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KRAS—skin cancer	2.1e-05	0.000316	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KRAS—skin cancer	2.07e-05	0.000312	CbGpPWpGaD
Thalidomide—FGFR2—Disease—BRAF—skin cancer	2.06e-05	0.00031	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLIN2—skin cancer	2.05e-05	0.000309	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—skin cancer	2.01e-05	0.000303	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KRAS—skin cancer	1.99e-05	0.0003	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ENO2—skin cancer	1.99e-05	0.000299	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.96e-05	0.000295	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CSPG4—skin cancer	1.93e-05	0.000291	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FOXO4—skin cancer	1.93e-05	0.000291	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TERT—skin cancer	1.92e-05	0.000289	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KRAS—skin cancer	1.88e-05	0.000284	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ENO2—skin cancer	1.87e-05	0.000282	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ENO2—skin cancer	1.87e-05	0.000281	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—skin cancer	1.86e-05	0.00028	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TERT—skin cancer	1.82e-05	0.000274	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—skin cancer	1.78e-05	0.000268	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—skin cancer	1.78e-05	0.000268	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ENO2—skin cancer	1.76e-05	0.000266	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—skin cancer	1.76e-05	0.000265	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—skin cancer	1.69e-05	0.000255	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—skin cancer	1.68e-05	0.000254	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—skin cancer	1.66e-05	0.000251	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CSPG4—skin cancer	1.65e-05	0.000249	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—skin cancer	1.6e-05	0.000241	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—skin cancer	1.53e-05	0.000231	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—BRAF—skin cancer	1.52e-05	0.000229	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—skin cancer	1.48e-05	0.000223	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ERCC2—skin cancer	1.45e-05	0.000219	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO2—skin cancer	1.44e-05	0.000217	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BRAF—skin cancer	1.44e-05	0.000217	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—skin cancer	1.4e-05	0.000211	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.38e-05	0.000208	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERCC2—skin cancer	1.38e-05	0.000208	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ENO2—skin cancer	1.31e-05	0.000198	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—skin cancer	1.29e-05	0.000195	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TERT—skin cancer	1.29e-05	0.000195	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—skin cancer	1.27e-05	0.000192	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—skin cancer	1.21e-05	0.000182	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ERCC2—skin cancer	1.15e-05	0.000174	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.13e-05	0.00017	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO2—skin cancer	1.12e-05	0.000169	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—skin cancer	1.11e-05	0.000168	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ERCC2—skin cancer	1.09e-05	0.000164	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ERCC2—skin cancer	1.08e-05	0.000163	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—skin cancer	1.08e-05	0.000163	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—skin cancer	1.03e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.03e-05	0.000155	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—skin cancer	1.03e-05	0.000154	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ERCC2—skin cancer	1.02e-05	0.000154	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—skin cancer	1.02e-05	0.000154	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—skin cancer	9.81e-06	0.000148	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—skin cancer	9.55e-06	0.000144	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—skin cancer	9.47e-06	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—skin cancer	9.06e-06	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—skin cancer	9.06e-06	0.000137	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.79e-06	0.000132	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—skin cancer	8.71e-06	0.000131	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ERCC2—skin cancer	8.38e-06	0.000126	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—skin cancer	8.22e-06	0.000124	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—skin cancer	7.8e-06	0.000118	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ERCC2—skin cancer	7.64e-06	0.000115	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—skin cancer	7.3e-06	0.00011	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—skin cancer	6.99e-06	0.000105	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—skin cancer	6.93e-06	0.000104	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—skin cancer	6.69e-06	0.000101	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—skin cancer	6.63e-06	9.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ERCC2—skin cancer	6.53e-06	9.84e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—skin cancer	6.51e-06	9.81e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—skin cancer	6.5e-06	9.79e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—skin cancer	6.43e-06	9.68e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—skin cancer	6.34e-06	9.56e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—skin cancer	6.14e-06	9.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—skin cancer	5.53e-06	8.33e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—skin cancer	5.02e-06	7.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—skin cancer	4.7e-06	7.08e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—skin cancer	4.58e-06	6.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—skin cancer	4.5e-06	6.78e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—skin cancer	3.91e-06	5.9e-05	CbGpPWpGaD
